Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Nurix Therapeutics, Inc.
Arcus Biosciences, Inc.
Seagen Inc.
Celldex Therapeutics
Fate Therapeutics
Genzada Pharmaceuticals USA, Inc.
Ascentage Pharma Group Inc.
Incyte Corporation
University of Chicago
Altor BioScience
Memorial Sloan Kettering Cancer Center
Novartis
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Cancer Research UK
Case Comprehensive Cancer Center